Chicago, Illinois 60637

  • Prostate Cancer


RATIONALE: Vaccines made from a patient's white blood cells may make the body build an immune response to kill cancer cells. Interleukin-12 may kill cancer cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. Combining vaccine therapy with interleukin-12 may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy combined with interleukin-12 in treating patients who have metastatic prostate cancer that has not responded to hormone therapy.

Study summary:

OBJECTIVES: - Determine whether immunization with prostate-specific membrane antigen-pulsed autologous peripheral blood mononuclear cells and interleukin-12 can promote specific T-cell priming in patients with metastatic hormone-refractory prostate cancer. - Determine the clinical response in patients treated with this regimen. OUTLINE: Patients receive prostate-specific membrane antigen-pulsed autologous peripheral blood mononuclear cells subcutaneously (SC) on day 1 and interleukin-12 SC on days 1, 3, and 5. Treatment repeats every 21 days for 3-9 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months. PROJECTED ACCRUAL: A total of 12-37 patients will be accrued for this study within 37 weeks.


DISEASE CHARACTERISTICS: - Histologically confirmed metastatic adenocarcinoma of the prostate - HLA-A2 positive - Progressive measurable systemic disease - PSA at least 5 ng/mL with 2 consecutive rising PSA levels at least 1 week apart and no measurable disease OR - Objective evidence of disease progression by a 20% increase in the sum of longest diameter of all target lesions or evidence of new lesions by CT or bone scan regardless of PSA status - Lesions must be at least 1 cm to be considered measurable - Progressive systemic disease after discontinuation of anti-androgen therapy - Previously treated with orchiectomy (testosterone less than 50 ng/mL) OR luteinizing hormone-releasing hormone (LHRH) analogue therapy with or without anti-androgens - If on LHRH analogue therapy, must continue therapy during study - Brain metastases allowed if previously treated, clinically stable, and weaned from prior corticosteroids PATIENT CHARACTERISTICS: Age: - Over 18 Performance status: - Karnofsky 70-100% Life expectancy: - At least 12 weeks Hematopoietic: - Absolute neutrophil count greater than 1,500/mm^3 - Hemoglobin greater than 9 g/dL - Platelet count greater than 100,000/mm^3 - No active gastrointestinal bleeding Hepatic: - Bilirubin less than 1.5 times upper limit of normal (ULN) - SGPT normal - Hepatitis B surface antigen negative Renal: - Creatinine less than 1.5 times ULN - Calcium less than 11 mg/dL Cardiovascular: - No significant cardiovascular disease - No cardiac arrhythmia requiring therapy Other: - Fertile patients must use effective barrier contraception - No intrinsic immunosuppression - HIV negative - No serious concurrent infection - No psychiatric illness that would preclude study compliance - No clinically significant autoimmune disease - No uncontrolled peptic ulcer disease - No history of inflammatory bowel disease PRIOR CONCURRENT THERAPY: Biologic therapy: - At least 4 weeks since prior biologic therapy Chemotherapy: - Not specified Endocrine therapy: - See Disease Characteristics - At least 4 weeks since prior flutamide - At least 6 weeks since prior bicalutamide or nilutamide - No concurrent systemic corticosteroids except physiologic replacement doses Radiotherapy: - Not specified Surgery: - See Disease Characteristics Other: - No concurrent immunosuppressive drugs (e.g., cyclosporine)



Primary Contact:

Study Chair
Thomas F. Gajewski, MD, PhD
University of Chicago

Backup Contact:


Location Contact:

Chicago, Illinois 60637
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 30, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.